On April 22, 2022 CEL-SCI Corporation (NYSE American: CVM) reported that two abstracts related to CEL-SCI’s pivotal Phase 3 head and neck cancer clinical trial were accepted at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting being held June 3-7, 2022 in Chicago, IL (Press release, Cel-Sci, APR 22, 2022, View Source [SID1234612875]). After a two-year hiatus, ASCO (Free ASCO Whitepaper) comes alive in June 2022 under the theme, "Advancing Equitable Cancer Care Through Innovation." ASCO (Free ASCO Whitepaper) is the largest cancer meeting in the world, bringing together thousands of cancer experts from academia, industry, patient advocacy and policy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

About Multikine

Multikine* (Leukocyte Interleukin, Injection) is an investigational cancer immunotherapy that is known to contain a mixture of natural human proinflammatory cytokines, the body’s immune system regulators including interleukins, interferons, chemokines, and colony stimulating factors which are elements of the body’s natural mix of defenses against cancer and other diseases. A patented, mass-produced, off the shelf, non-autologous biological investigational product, Multikine is manufactured using a proprietary process following Current Good Manufacturing Practice (cGMP) at CEL-SCI’s manufacturing facility near Baltimore, Maryland.

About Head and Neck Cancer

Approximately 890,000 new cases of head and neck cancer are diagnosed each year globally, of which approximately 68,000 are in the U.S. and 150,000 in Europe.